News
Pfizer’s ZAVZPRET™ (zavegepant) Migraine Nasal Spray Receives FDA Approval
Pfizer Inc. (NYSE: PFE) today announced the U.S. Food and Drug Administration (FDA) has approved ZAVZPRET™ (zavegepant), the first and only calcitonin gene-related peptide (CGRP) receptor
Agilent Again Named One of Barron’s 100 Most Sustainable Companies
For the sixth consecutive year, Agilent Technologies (NYSE: A) is ranked among the top 20 in Barron’s list of America’s 100 Most Sustainable Companies.
The ranking is based on the performance of
Agilent Announces Acquisition of e-MSion, Early-Stage Company Behind ECD Technology that Helps Accelerate Drug Development
Agilent Technologies Inc. (NYSE: A) today announced the acquisition of e-MSion, an early-stage company behind the innovative electron capture dissociation (ECD) technology known as the ExD cell.
Humana’s Economic Impact in Florida Totals $48 Billion
An independent economic research analysis estimated that leading health and well-being company Humana Inc. (NYSE: HUM) would contribute a total of $48 billion in overall economic impact in the
QuidelOrtho Receives De Novo FDA Authorization for Sofia® 2 SARS Antigen+ FIA
QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine
Humana Healthy Horizons Recommended by Indiana Family and Social Services Administration to Serve Medicaid Beneficiaries
Leading integrated health and wellness company Humana Inc. (NYSE: HUM) has been notified by the Indiana Family and Social Services Administration (FSSA) that FSSA is recommending Humana be awarded
Agilent Announces Global Distribution Agreement with Proscia to Accelerate Data-Driven Precision Medicine
Agilent Technologies Inc. (NYSE: A) today announced a multi-year distribution agreement with Proscia® – a leader in digital pathology – to offer a comprehensive digital diagnostic pathology system
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Agilent to Present at Barclays Global Healthcare Conference
Agilent Technologies Inc. (NYSE: A) today announced that Chief Financial Officer Bob McMahon will participate in a Q&A session at the Barclays Global Healthcare Conference in Miami Beach, Florida
QuidelOrtho to Participate in the Raymond James 44th Annual Institutional Investor Conference
QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and
Humana and Aledade Announce 10 Year Collaboration
Aledade, the nation’s largest network of independent primary care, and Humana Inc. (NYSE: HUM), leading health insurer and health care services company, have announced a 10-year collaboration to
Pfizer Receives Positive FDA Advisory Committee Votes Supporting Potential Approval for Vaccine Candidate to Help Combat RSV in Older Adults
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted that available data is adequate
Agilent Reports First-Quarter Fiscal Year 2023 Financial Results
Agilent Technologies Inc. (NYSE: A) today reported revenue of $1.76 billion for the first quarter ended January 31, 2023, an increase of 5% compared to the first quarter of 2022 and up 10% on a
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with Angela Hwang, Chief Commercial Officer, President, Global Biopharmaceutical
Agilent Announces Bravo NGS Automated Liquid Handling Platform with On-Deck Thermal Cycler
Agilent Technologies Inc. (NYSE: A) today announced the release of an on-deck thermal cycler (ODTC) that integrates with the Agilent Bravo NGS automated liquid handling platform. The optional ODTC
Agilent Announces Cell Analysis Workflow Automation for Immuno-Oncology, Virology, and Vaccine Development Markets
Agilent Technologies Inc. (NYSE: A) today announced their xCELLigence RTCA HT (real-time cell analysis high-throughput) platform now integrates with the BioTek BioSpa 8 Automated Incubator
Dexcom Announces Upcoming Conference Presentations
DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on the company at the following upcoming investor conferences:
-
Sean Christensen, Vice President, Finance and
Agilent Announces Cash Dividend of 22.5 Cents Per Share
Agilent Technologies Inc. (NYSE: A) today announced a quarterly dividend of 22.5 cents per share of common stock will be paid on April 26, 2023, to all shareholders of record as of the close of
Agilent Inspires at SLAS2023, Highlighting Innovative Automated Workflow Solutions
Agilent Technologies Inc. (NYSE: A) announced today that it will highlight a suite of automated laboratory workflow solutions at the SLAS2023 International Conference and Exhibition held February
Pfizer’s Elranatamab Receives FDA and EMA Filing Acceptance
Pfizer Inc. (NYSE:PFE) announced today that the U.S. Food and Drug Administration (FDA) has granted Priority Review for the company’s Biologics License Application (BLA) for elranatamab, an
Dexcom stellt Genauigkeit, Unkompliziertheit und Konnektivität des CGM-Portfolios auf der ATTD Conference in den Blickpunkt, da Zugang zu CGM weltweit zunimmt
DexCom, Inc. (NASDAQ: DXCM), der weltweit führende Anbieter im Bereich der kontinuierlichen Blutzuckermessung (CGM) in Echtzeit für Menschen mit Diabetes mellitus, wird die Leistungskraft seines
Dexcom Showcases Accuracy, Simplicity and Connectivity of Its CGM Portfolio at ATTD Conference as Access to CGM Expands Globally
DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, will showcase the strength of its CGM portfolio and unveil new clinical and
U.S. FDA Accepts Biologics License Application for Pfizer’s Respiratory Syncytial Virus Maternal Vaccine Candidate for Priority Review
Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for its respiratory syncytial virus (RSV)
Sartorius Stedim Biotech SA: Information on Document Availability
Pfizer Announces Positive TALZENNA® and XTANDI® Combination Data from Phase 3 TALAPRO-2 Study
Pfizer (NYSE: PFE) announced today positive results from the Phase 3 TALAPRO-2 study of TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI®